Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.3.1.21 (
CPT
)
4,580
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The present study demonstrates that dexamethasone and 8-(4-chlorophenylthio)adenosine 3',5'-monophosphate (
CPT
-cAMP), a cAMP analog, increase the substrate flux through
branched-chain keto acid dehydrogenase
(
BCKDH
) in primary rat hepatocytes cultured in defined medium. Maximum response (2.7-fold increase in flux) was observed when hepatocytes were cultured with 1 microM dexamethasone plus 50 microM
CPT
-cAMP for 24 h. This increase in the flux rate was accompanied by significant increases in both the basal and total activities of
BCKDH
(2.2- and 2.0-fold, respectively), without any significant change in the activity state of this enzyme. The increase in
BCKDH
activity was the result of increased protein mass of E1 alpha (3.2-fold), E1 beta (2.9-fold), and E2 (1.6-fold) subunits of
BCKDH
, indicating that E2 is the limiting subunit for the expression of
BCKDH
. The relative abundance of mRNAs encoding the E1 alpha, E1 beta, and E2 subunits of
BCKDH
increased by 7.4-, 21.7-, and 4.8-fold, respectively. We conclude that increased flux through
BCKDH
in hepatocytes cultured with dexamethasone and
CPT
-cAMP is due to increased expression of
BCKDH
subunit genes. However, nonstoichiometric expression of individual subunits and the corresponding mRNAs suggests regulation of
BCKDH
also at translational and post-translational steps.
...
PMID:Regulation of gene expression of branched-chain keto acid dehydrogenase complex in primary cultured hepatocytes by dexamethasone and a cAMP analog. 803 10
